)
Visual24 Oct 2025
The rise of Alphabet
SynAct Pharma (SYNACT) investor relations material
SynAct Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary20 Aug, 2025
Executive summary
Focused on advancing resomelagon (AP1189) for inflammatory and autoimmune diseases, especially rheumatoid arthritis (RA), and host-directed therapy in viral infections, with a clear two-track development strategy.
ADVANCE Phase 2b study in newly diagnosed severe RA is on track, aiming to complete enrollment by end of 2025 and report key data in Q1 2026.
Initiated a Phase 2 study in Dengue and planning a Phase 2 study in Polymyalgia Rheumatica (PMR) in H2 2025.
Strengthened financial position through a SEK 37 million share issue, SEK 30 million credit facility, and warrant conversions, extending runway into 2027.
Financial highlights
Net sales were SEK 0 for both Q2 and H1 2025, consistent with prior periods.
Q2 operating expenses increased 58% year-over-year to SEK 30,345 thousand; H1 operating expenses rose 30% to SEK 58,443 thousand.
Q2 loss after tax was SEK 27,522 thousand (vs. SEK 18,628 thousand in Q2 2024); H1 loss after tax was SEK 52,207 thousand (vs. SEK 43,534 thousand in H1 2024).
Q2 EPS was -0.56 SEK (vs. -0.47 SEK); H1 EPS was -1.07 SEK (vs. -1.16 SEK).
Cash and cash equivalents at June 30, 2025, were SEK 68,890 thousand (vs. SEK 62,799 thousand a year earlier).
Outlook and guidance
No revenue expected until at least 2026, post-Phase 2 program completion.
Current cash and recent financings are sufficient to fund operations for at least the next 12 months, with runway extended into 2027.
ADVANCE study enrollment to complete by end of 2025; key data expected Q1 2026.
IMN study: future resource allocation?
Funding sources for 2027 runway extension
R&D project prioritization with new funding?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next SynAct Pharma earnings date
Q3 202530 Oct, 2025
Next SynAct Pharma earnings date
Q3 202530 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
SynAct Pharma AB, develops medicines for acute deterioration in inflammatory diseases. The company's lead product, Synacto®, is a mix of three anti-inflammatory protease inhibitors for the treatment of patients who have recently had a heart attack, have re-opened their old heart wounds due to surgery, or are going to undergo procedures in which blood clotting is needed. SynAct Pharma AB is based in Lund, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage